A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients
Niels van Mourik, Rombout B. E. van Amstel, Marleen A. Slim, Lonneke A. van Vught et autres
BACKGROUND: Histones released in response to cellular injury are important mediators of organ failure and death in sepsis. Preclinical studies demonstrate that neutralization of histones in sepsis is associated with improved outcome. M6229 is a low-anticoagulant heparin able to neutralize histones. We …
nl (code pays fourni par la source)
3 citations
Intensive Care Medicine Experimental